<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03538717</url>
  </required_header>
  <id_info>
    <org_study_id>A4061089</org_study_id>
    <secondary_id>AXILONG</secondary_id>
    <nct_id>NCT03538717</nct_id>
  </id_info>
  <brief_title>&quot;Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC&quot;</brief_title>
  <official_title>Análisis Retrospectivo De Factores Clínicos Asociados A Un Mayor Beneficio Con Axitinib En Cáncer Renal Metastásico. (Estudio Axilong)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective study to collect data from Patients with advanced/metastatic renal cell
      carcinoma previously treated with Axitinib under standard clinical practice, to describe the
      clinical profile of the patients with a long response to Axitinib and to try to identify
      clinical factors which could be related with the long response to Axitinib, through the
      comparison between long responder patients and a group of refractory patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe the clinical profile of patients with a long response to Axitinib and to identify
      clinical factors which could be related with the long response to Axitinib, through the
      comparison between long responder patients and a group of refractory patients.

      For this study are defined as &quot;long responder&quot;, those patients who has a Progression Free
      Survival (PFS) of at least 9 months since the initiation of Axitinib treatment, and
      &quot;refractory patients&quot; those who have Progression Disease (PD) in the first response
      assessment since the initiation of Axitinib treatment (estimated PFS ≤3 months]

      Secondary Objectives

        -  To describe the efficacy of Axitinib treatment in the long responders group, and in
           relation with the treatment received before Axitinib, in terms of PFS, ORR, CB, OS, TTP
           ...

        -  To describe the tolerability and drug management of Axitinib in this population.

        -  To describe treatment received after Axitinib in this population.

      Study procedures:

      For the recruitment, the Investigator should review the inclusion / exclusion criteria. In
      case of patients alive at the moment of the inclusion, the investigator will require them to
      sign the IC.

      With the data available in the medical records, the information requested will be recorded in
      the electronic data collection tool.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with clinical characteristics which are significant associated with PFS longer than 9 months. Comparison of clinical profile of patients with PFS longer than 9months vs refractory patients</measure>
    <time_frame>Throught study completion, an average of 9 months.</time_frame>
    <description>Diferences in the clinical profile of patients who have achieved a good response to Axitinib (PFS longer than 9 months) vs Axitinib refractory patients (PD as best response). Number of patients with clinical characteristics which are significant associated with PFS longer than 9 months.</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <eligibility>
    <study_pop>
      <textblock>
        - Age ≥ 18 years

          -  Patients with advanced or metastatic renal cell carcinoma, histologically confirmed,
             with at least one radiological response assessment

          -  Patients who had received Axitinib treatment in second or further line with a PFS ≥9
             months or DP (disease progression) at the first tumor assessment.

          -  For the patients alive at the moment of the inclusion, patients must have a signed
             informed consent document
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

               -  Patients with advanced or metastatic renal cell carcinoma, histologically
                  confirmed, with at least one radiological response assessment

               -  Patients who had received Axitinib treatment in second or further line with a PFS
                  ≥9 months or DP (disease progression) at the first tumor assessment.

               -  For the patients alive at the moment of the inclusion, patients must have a
                  signed informed consent document

        Exclusion Criteria:

          -  Axitinib received out of the approved indication Patients who do not meet any of the
             inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Mutua Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Principe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Parla</city>
        <state>Madrid</state>
        <zip>28981</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Elena</name>
      <address>
        <city>Valdemoro</city>
        <state>Madrid</state>
        <zip>28342</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HU de Navarra, Pamplona</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Cuesta, Santa Cruz De Tenerife</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Pau i Santa Creu</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HU De León</name>
      <address>
        <city>León</city>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti (HULA_ Lugo)</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15076</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de Segovia</name>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Vigo- Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061089&amp;StudyName=An%C3%A1lisis+Retrospectivo+De+Factores+Cl%C3%ADnicos+Asociados+A+Un+Mayor+Beneficio+Con+Axitinib+En+C%C3%A1ncer+Renal+Metast%C3%A1sico.+%28estudio+Axilong%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axitinib,</keyword>
  <keyword>Renal Carcinoma,</keyword>
  <keyword>Long responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

